Scarica l'app Stockscreener
24.01
3.27%
0.76
Dopo l'orario di chiusura:
24.24
0.23
+0.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$23.25
Aprire:
$23.42
Volume 24 ore:
4.49M
Relative Volume:
0.62
Capitalizzazione di mercato:
$2.35B
Reddito:
$2.48B
Utile/perdita netta:
$-57.96M
Rapporto P/E:
-31.65
EPS:
-0.7585
Flusso di cassa netto:
$-453.97M
1 W Prestazione:
+5.26%
1M Prestazione:
+24.60%
6M Prestazione:
-61.52%
1 anno Prestazione:
-80.94%
Intervallo 1D:
$23.02
$24.48
Intervallo di 1 settimana:
$22.79
$24.48
Portata 52W:
$10.41
$138.81
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Nome
Sarepta Therapeutics Inc
Settore
Industria
Telefono
617-274-4000
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Confronta SRPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
24.01 | 2.43B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-22 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Iniziato | Bernstein | Mkt Perform |
| 2025-07-29 | Reiterato | H.C. Wainwright | Sell |
| 2025-07-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Iniziato | Citigroup | Sell |
| 2025-07-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Downgrade | Mizuho | Outperform → Neutral |
| 2025-07-21 | Downgrade | Needham | Hold → Underperform |
| 2025-07-21 | Downgrade | UBS | Buy → Neutral |
| 2025-07-18 | Downgrade | Needham | Buy → Hold |
| 2025-06-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Downgrade | TD Cowen | Buy → Hold |
| 2025-06-17 | Iniziato | Wolfe Research | Peer Perform |
| 2025-06-16 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-06-16 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Downgrade | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Iniziato | Wells Fargo | Overweight |
| 2025-04-02 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-11-27 | Reiterato | Needham | Buy |
| 2024-11-25 | Iniziato | H.C. Wainwright | Sell |
| 2024-11-07 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-07-29 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-13 | Ripresa | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-21 | Iniziato | Wedbush | Outperform |
| 2023-10-31 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-04 | Iniziato | Citigroup | Buy |
| 2023-03-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Reiterato | BTIG Research | Buy |
| 2022-12-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Reiterato | Needham | Buy |
| 2021-12-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-08-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-01-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-11 | Downgrade | UBS | Buy → Neutral |
| 2021-01-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Iniziato | Mizuho | Buy |
| 2019-11-01 | Iniziato | Guggenheim | Buy |
| 2019-08-21 | Reiterato | Needham | Buy |
| 2019-07-09 | Reiterato | Morgan Stanley | Overweight |
| 2019-07-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-11 | Reiterato | Credit Suisse | Outperform |
| 2018-10-12 | Iniziato | Bernstein | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Reiterato | RBC Capital Mkts | Outperform |
| 2018-09-14 | Ripresa | BofA/Merrill | Buy |
| 2018-09-06 | Iniziato | Credit Suisse | Outperform |
| 2018-08-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Reiterato | Robert W. Baird | Outperform |
| 2018-06-20 | Reiterato | Needham | Buy |
| 2018-06-19 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Relative strength of Sarepta Therapeutics Inc. in sector analysisJuly 2025 Big Picture & Technical Buy Zone Confirmations - newser.com
Is Sarepta Therapeutics Inc. trending in predictive chart models2025 Market Trends & Growth Focused Stock Pick Reports - newser.com
How Sarepta Therapeutics Inc. (AB3A) stock expands through international marketsShare Buyback & Free Reliable Trade Execution Plans - newser.com
Analyzing drawdowns of Sarepta Therapeutics Inc. with statistical tools2025 Investor Takeaways & Stock Portfolio Risk Management - newser.com
Combining machine learning predictions for Sarepta Therapeutics Inc.Earnings Risk Report & Advanced Technical Signal Analysis - newser.com
Is Sarepta Therapeutics Inc. (AB3A) stock testing key supportJuly 2025 Spike Watch & Growth Focused Investment Plans - newser.com
What technical charts say about Sarepta Therapeutics Inc. stock2025 Year in Review & Verified Stock Trade Ideas - newser.com
What market sentiment indicators show for Sarepta Therapeutics Inc. (AB3A) stockJuly 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - newser.com
When is the best time to exit Sarepta Therapeutics Inc.Quarterly Portfolio Review & Reliable Intraday Trade Plans - newser.com
SAREPTA THERAPEUTICS Earnings Preview: Recent $SRPT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Can Sarepta Therapeutics Inc. (AB3A) stock attract analyst upgradesQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - newser.com
Is Sarepta Therapeutics Inc. stock supported by strong cash flows2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
What makes Sarepta Therapeutics Inc. (AB3A) stock appealing to growth investorsBear Alert & Weekly High Potential Stock Alerts - newser.com
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $16.00 - MarketBeat
Is Sarepta Therapeutics Inc. stock attractive for passive investors2025 Buyback Activity & Daily Profit Maximizing Trade Tips - newser.com
What to do if you’re stuck in Sarepta Therapeutics Inc.Volume Spike & Free Risk Controlled Daily Trade Plans - newser.com
Is Sarepta Therapeutics Inc. stock ready for a breakoutJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
Is Sarepta Therapeutics Inc. stock a good choice for value investors2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
How Sarepta Therapeutics Inc. stock benefits from global expansion2025 Major Catalysts & AI Powered Buy/Sell Recommendations - newser.com
Will Sarepta Therapeutics Inc. stock benefit from sector rotationJuly 2025 PreEarnings & Reliable Intraday Trade Alerts - newser.com
Sarepta Therapeutics’ Long-term Study on SRP-9001: A Boost for Investor Confidence? - TipRanks
Will breakout in Sarepta Therapeutics Inc. lead to full recoveryWeekly Risk Report & Community Consensus Trade Signals - newser.com
How to escape a deep drawdown in Sarepta Therapeutics Inc.2025 Winners & Losers & AI Driven Stock Reports - newser.com
Sarepta’s Gene Therapy Study: A Potential Game-Changer for Duchenne Muscular Dystrophy - TipRanks
Piper Sandler Maintains Sarepta Therapeutics (SRPT) Neutral Recommendation - Nasdaq
Interesting SRPT Put And Call Options For December 19th - Nasdaq
Piper Sandler Maintains Neutral Rating on SRPT, Raises Price Tar - GuruFocus
Sarepta Therapeutics (SRPT) to Release Quarterly Earnings on Monday - MarketBeat
Allianz Asset Management GmbH Has $252,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Can Sarepta Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Market Summary & Real-Time Buy Zone Alerts - fcp.pa.gov.br
Will Sarepta Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Technicals & Free Weekly Watchlist of Top Performers - fcp.pa.gov.br
Using Bollinger Bands to evaluate Sarepta Therapeutics Inc.Quarterly Portfolio Review & Entry Point Confirmation Signals - newser.com
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Hold" by Analysts - MarketBeat
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results - BioSpace
Is Sarepta Therapeutics Inc. stock trading near support levels2025 Market Trends & Free Expert Verified Stock Movement Alerts - fcp.pa.gov.br
Sarepta’s Gene Therapy Study for Young DMD Patients: A Market Game-Changer? - TipRanks
Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):